-
Published on Sep 13, 2016
Amryt Pharma (FAST) chief executive Joe Wiley speaks to Proactive Investors
Stocktube about the drug discovery group’s busy half year, which saw two
key acquisitions.
“We got a huge amount achieved in a relatively short period of time,”
He added: “We set up Amryt Pharma to be a company focussed on developing and commercialising products in the rare disease or orphan disease space.”
The Amryt boss talks in detail about the group’s newly acquire lead product, Episalvan, to treat a skin disorder called Epidermolysis Bullosa or EB, as well as the company’s portfolio of other treatments.
http://www.4-traders.com/AMRYT-PHARMA-PLC-27330346/
“We got a huge amount achieved in a relatively short period of time,”
He added: “We set up Amryt Pharma to be a company focussed on developing and commercialising products in the rare disease or orphan disease space.”
The Amryt boss talks in detail about the group’s newly acquire lead product, Episalvan, to treat a skin disorder called Epidermolysis Bullosa or EB, as well as the company’s portfolio of other treatments.
http://www.4-traders.com/AMRYT-PHARMA-PLC-27330346/
No comments:
Post a Comment